PTC Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTCT and other ETFs, options, and stocks.

About PTCT

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ. 

CEO
Matthew B. Klein
CEOMatthew B. Klein
Employees
939
Employees939
Headquarters
Warren, New Jersey
HeadquartersWarren, New Jersey
Founded
1998
Founded1998
Employees
939
Employees939

PTCT Key Statistics

Market cap
6.07B
Market cap6.07B
Price-Earnings ratio
8.82
Price-Earnings ratio8.82
Dividend yield
Dividend yield
Average volume
999.94K
Average volume999.94K
High today
$78.38
High today$78.38
Low today
$75.31
Low today$75.31
Open price
$76.87
Open price$76.87
Volume
1.35M
Volume1.35M
52 Week high
$87.50
52 Week high$87.50
52 Week low
$35.95
52 Week low$35.95

Stock Snapshot

As of today, PTC Therapeutics(PTCT) shares are valued at $75.60. The company's market cap stands at 6.07B, with a P/E ratio of 8.82.

During the trading session on 2026-01-28, PTC Therapeutics(PTCT) shares reached a daily high of $78.38 and a low of $75.31. At a current price of $75.60, the stock is +0.4% higher than the low and still -3.5% under the high.

Trading activity shows a volume of 1.35M, compared to an average daily volume of 999.94K.

Over the past 52 weeks, PTC Therapeutics(PTCT) stock has traded between a high of $87.50 and a low of $35.95.

Over the past 52 weeks, PTC Therapeutics(PTCT) stock has traded between a high of $87.50 and a low of $35.95.

PTCT News

TipRanks 1d
PTC Therapeutics assumed with Overweight from Equal Weight at Barclays

Barclays upgraded PTC Therapeutics (PTCT) to Overweight from Equal Weight with a price target of $119, up from $68, after assuming coverage of the name. Barclay...

Simply Wall St 3d
A Look At PTC Therapeutics Valuation After New 2026 Revenue Guidance And Morgan Stanley Support

PTC Therapeutics (PTCT) recently issued full year 2026 product revenue guidance of US$700 million to US$800 million, excluding Evrysdi royalties and collaborati...

A Look At PTC Therapeutics Valuation After New 2026 Revenue Guidance And Morgan Stanley Support
Simply Wall St 5d
Is PTC Therapeutics Still Attractive After A 65% One-Year Share Price Jump

If you are trying to figure out whether PTC Therapeutics is genuinely good value or just riding biotech sentiment, it helps to line up the price against what th...

Is PTC Therapeutics Still Attractive After A 65% One-Year Share Price Jump

Analyst ratings

67%

of 15 ratings
Buy
66.7%
Hold
26.7%
Sell
6.7%

People also own

Based on the portfolios of people who own PTCT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.